Ask anything about research
Search papers, query evidence, get expert commentary — all in one place
ACC 2026 Late-Breaking Trials
Live trial results, expert commentary, and discussion with 10+ trial authors
Hot Research Today
Papers from every journal, all in one place
Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation
Does left atrial appendage closure reduce a composite end point of stroke, systemic embolism, major bleeding, or cardiovascular or unexplained death in patients with atrial fibrillation at high risk for stroke and bleeding?
Result: Left atrial appendage closure was not noninferior to physician-directed best medical care with regard to a composite end point of stroke, systemic embolism, major bleeding, or cardiovascular or unexplained death.
“Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation | New England Journal of Medicine https://t.co/fELezUF2Jl”
In general, the benefit from any percutaneous intervention in cardiology is often the greatest with regard to the most acute or life-threatening problem the patient is facing. In contrast, in clinical situations in which the patient’s life is not directly at risk and the symptoms are controllable by medical treatment, conservative management should always be considered to be an equally effective alternative.
Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation
Does device-based left atrial appendage closure prevent a composite of death from cardiovascular causes, stroke, or systemic embolism compared to NOAC therapy in patients with atrial fibrillation who are candidates for anticoagulation?
Result: Device-based left atrial appendage closure was noninferior to NOAC therapy with respect to the primary composite endpoint and superior for non-procedure-related bleeding at 3 years.
“Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation | New England Journal of Medicine https://t.co/fELezUF2Jl”
In patients with nonvalvular atrial fibrillation suitable for anticoagulation, left atrial appendage closure using the Watchman FLX device, at 3 years was noninferior to NOACs for the composite primary endpoint [of] cardiovascular death, stroke, and systemic embolization, and significantly reduced clinically relevant nonprocedural bleeding.
Discontinuation of Beta-Blocker Therapy after Myocardial Infarction
Does discontinuation of beta-blocker therapy prevent adverse cardiovascular events in patients who received beta-blocker therapy beyond the first year after a myocardial infarction?
Result: Discontinuation of beta-blocker therapy was noninferior to continuation with respect to a composite of death from any cause, recurrent myocardial infarction, or hospitalization for heart failure.
At subsequent visits, it’s always an opportunity to revisit [and ask] can we reduce this pill burden? This study demonstrated in a more definitive fashion than the ABYSS study that yes, at 1 year, it is safe in patients with normal ejection fraction and no atrial fibrillation to stop that beta-bl...
Left bundle branch area vs biventricular pacing for cardiac resynchronization therapy: the LEFT-BUNDLE-CRT trial
Does left bundle branch area pacing provide non-inferior outcomes compared to biventricular pacing in CRT candidates with typical LBBB?
Result: LBBAP-CRT was not shown to be non-inferior to BiVP-CRT, although both strategies yielded high response rates and similar clinical outcomes.
“Left bundle branch area vs biventricular pacing for cardiac resynchronization therapy: the LEFT-BUNDLE-CRT trial In CRT candidates with typical LBBB, LBBAP-CRT was not shown to be non-inferior to BiVP-CRT. Both strategies yielded high response rates and similar clinical https://t.co/nJkdSOOOYM”
We now have randomized data showing that [LBBAP] is a very credible CRT option, with procedural advantages in some settings and clinical outcomes that are at least broadly comparable to BiV-CRT in selected populations. But I would still be cautious about overinterpreting the current evidence. These trials are important, but they do not yet justify a one-size-fits-all conclusion that LBBAP should replace conventional CRT across the board.
Real-World Outcomes of Transcatheter Tricuspid Valve Replacement
Does Transcatheter Tricuspid Valve Replacement (TTVR) improve safety and effectiveness at 30 days in real-world patients with severe TR?
Result: Thirty-day outcomes demonstrated acceptable safety, near-complete TR elimination, and significant health status improvements, with lower rates of new CIED implantation and bleeding than in randomized trials.
“Real-World Outcomes of Transcatheter Tricuspid Valve Replacement https://t.co/594BIM51cc”
These findings show that transcatheter tricuspid valve replacement is translating well from the clinical trial setting into routine practice across the United States. In a large, older and medically complex patient population, we saw very high procedural success, near-complete elimination of tricuspid regurgitation, and rapid improvement in how patients feel and function.
Sotatercept for Combined Post- and Pre-capillary Pulmonary Hypertension Associated With Heart Failure: Results from the Phase 2, Randomized, Placebo-Controlled CADENCE Study
Does sotatercept improve pulmonary vascular resistance in adults with combined post- and pre-capillary pulmonary hypertension associated with heart failure with preserved ejection fraction?
Result: Sotatercept significantly reduced pulmonary vascular resistance compared to placebo, with a Hodges-Lehmann shift estimate of -1.02 Wood units (95% CI, -1.81 to -0.23; P=0.004) for the 0.3 mg/kg dose and -0.75 Wood units (95% CI, -1.52 to 0.03; P=0.024) for the 0.7 mg/kg dose.
Similar to PAH trials, the benefits of sotatercept transcend the relatively modest reductions in resting PVR and highlight the importance of targeting inflammation, cell proliferation and endothelial function in HFpEF. As the biology of ligand traps evolves, sotatercept marks the first step in leveraging the power of signaling networks to reverse fibrosis and cellular hypertrophy. Notably, the CADENCE trial emphasizes the importance of targeting underlying biologic mechanisms responsible for disease, versus focusing solely on improving hemodynamic parameters.
Effect of baxdrostat on ambulatory blood pressure in patients with resistant hypertension (Bax24): a phase 3, randomised, double-blind, placebo-controlled trial
Does baxdrostat reduce 24 h ambulatory systolic blood pressure in patients with resistant hypertension?
Result: At 12 weeks, the estimated placebo-corrected difference in change from baseline in least-squares mean 24 h ambulatory SBP was −14.0 mm Hg (95% CI −17.2 to −10.8; p<0.0001).
The landmark results from Bax24 Phase III trial demonstrate that patients with the hardest-to-control hypertension treated with baxdrostat achieved a highly clinically meaningful 14 mmHg placebo-adjusted reduction in 24-hour systolic blood pressure, which could transform treatment practice. It's remarkable to see this magnitude of reduction coupled with the fact that just over 70% of baxdrostat patients achieved guideline targets, consistently over 24 hours.
Endovascular Therapy for Post-Thrombotic Syndrome — A Randomized Trial
Does endovascular therapy improve post-thrombotic syndrome severity and health-related quality of life in patients with moderate or severe post-thrombotic syndrome and iliac-vein obstruction?
Result: Endovascular therapy led to less severe post-thrombotic syndrome and better health-related quality of life than standard care over a 6-month period, but with a higher risk of bleeding.
“C-TRACT is out in @NEJM. In 225 patients with moderate-severe #PTS and iliac-vein obstruction, endovascular therapy reduced PTS severity and improved QoL at 6 months vs standard care. Great leadership by Suresh Vedantham. Full study: https://t.co/TUS5orJz9P https://t.co/jKWL4khJ8Q”
Many patients with PTS suffer in silence because few physicians are aware of this complication or know how to effectively treat it. This study suggests that even severe PTS is, in fact, a treatable condition in many patients.
Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years
Does early surgery reduce operative mortality or cardiovascular death in asymptomatic patients with very severe aortic stenosis?
Result: Early surgery led to a lower risk of a composite of operative mortality or death from cardiovascular causes than conservative care at 10 years.
“Small numbers of patients but dramatic results! “Early Surgery or Conservative Care for Asymptomatic Aortic Stenosis at 10 Years” | New England Journal of Medicine https://t.co/qapySaSxAX”
The lack of convergence of the curves for death from cardiovascular causes and death from any causes over this prolonged period of follow-up underscores the sustained benefits of early surgery. Accordingly, we believe that early aortic valve replacement may be the preferred strategy for asymptoma...
Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease
Key Finding: Adjunctive prednisolone added to standard primary treatment for Kawasaki disease did not reduce the incidence of coronary-artery lesions at 1 month after illness onset.
“なんとNEJM Randomized Trial of Adjunctive Prednisolone for Kawasaki Disease | New England Journal of Medicine https://t.co/lXJVbmWINA”